The FDA on December 9, 2022, approved TECENTRIQ® (Atezolizumab) for adult and pediatric patients 2 years of age and older with unresectable or metastatic Alveolar Soft Part Sarcoma (ASPS). TECENTRIQ® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
